Direct dopaminergic responsiveness of activity performance
Objective: To assess the direct dopaminergic responsiveness of motor and process aspects of activity performance in people with parkinsonian disorders, and to compare this to…Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.
Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…Effects of dopaminergic medication on executive function in Parkinson’s disease differs according to the clinical stage
Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study
Objective: To investigate the effect of levodopa on articulatory movement during Cantonese plosive production in individuals with Parkinson's disease (PD) by comparing kinematic parameters before…Supplement use in PD is associated with delayed initiation of dopaminergic therapy
Objective: To describe supplement use among early PD patients, and to determine its association with time to initiation of dopamine replacement therapy (DRT). Background: Earlier…Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)
Objective: To provide suggested guidance on how to select appropriate candidates for therapy with carbidopa/levodopa enteral suspension (CLES) based on published literature. Background: The introduction…Healthcare burden of Parkinson’s disease
Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…Duodopa for the treatment of severe restless legs syndrome
Objective: To describe the outcome of a patient with restless legs syndrome (RLS) and augmentation phenomena that was treated with Duodopa in continuous infusion. Background:…Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease
Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »